

# WEEKLY SNAPSHOT

## MEDIA NEWS + TRENDS

This weekly e-letter will highlight important media reports and call out any key trends that demonstrate how the landscape is evolving and accelerating in today's market environment. The update will also highlight action that has been initiated by OPPI in media.



### Need to know

- Breach of promise on IPR policy?... [Frontline](#)
- National IPR policy relook: Government moves slowly... [Business Standard](#)
- Differences on IPR between India and US widen... [Mint](#)
- Bring 12 cancer drugs under price control: Tata hosp... [The Times of India](#)
- NPPA invites comments on Tata Memorial list of cancer drugs... [The Economic Times](#)
- Pharma opportunity: developed markets to spend more on drugs... [Mint](#)
- US industry patent lobby meeting with judges foiled... [The Economic Times](#)
- Modi urged to stand up to US pressure to change patent law... [The Times of India](#)
- Affordable healthcare is beyond compulsory licenses, US tells India... [Business Standard](#)
- High cost of drugs: US looks to provide relief for patients... [The Economic Times](#)
- Cut duty on generics, US tells India... [The Times of India](#)



### Good to know

- India, US agree to step up bilateral ties, establish technical dialogue to promote cooperation... [The Economic Times](#)
- MSF urges PM to take stern stand against weakening of Indian patent law under US pressure... [Pharmabiz](#)
- India's patent problems... [Mint](#)
- Is it safe to have that capsule?... [Business Standard](#)
- Concern in Rajya Sabha over rise in prices of essential medicines... [The Economic Times](#)
- Govt plans to bring all pharma related depts under one roof... [The Economic Times](#)
- Our gods in white coats?: Antara Dev Sen... [The Asian Age](#)
- No Breakthroughs As Indo-US Trade Forum Meets... [Business World](#)
- Intel wants govt to strengthen protection for trade secrets under IPR policy... [The Economic Times](#)
- The price of failure... [The Economist](#)



### Want to know

- Health insurance for all likely in January... [The Times of India](#)
- Centre to harmonise drug procurement policy for free medicine under NHM... [Pharmabiz](#)
- MCI summons 300 doctors for promoting costly brands of Ahmedabad based drug co... [Pharmabiz](#)
- Billing for wallet shock... [Business Standard](#)
- Health for all... [Business Standard](#)
- Steps Taken by Govt. to Accelerate Pace of Reduction for MMR to Achieve MDG Goals... [Business Standard](#)
- Decent healthcare for all... [DNA](#)
- SAARC looks towards achieving universal health coverage, eliminating poverty... [Business Standard](#)
- Sterilization deaths due to filthy OT and toxic drugs: Report... [The Times of India](#)
- Crisis In Pharma R&D: It Costs \$2.6 Billion To Develop A New Medicine; 2.5 Times More Than In 2003... [Forbes](#)

- US urges India to toughen patent laws to draw investors... [The Economic Times](#)
- Overdependence on China for drug ingredients worries NSA... [The Times of India](#)
- Cabinet Secretary to meet officials, ind tomorrow on ease of business... [The Economic Times](#)

---

## QUOTES OF THE WEEK

- “Science and technology has to become part of the country’s economic agenda. India invests 0.6 per cent of its GDP on research and development, compared to the US which spends 3 per cent and Israel’s 5 per cent of its GDP. Scientists can become entrepreneurs. Scientists must realise the value of what they were doing and the need to monetise innovations. There is a lack of an IP-oriented culture in India. Unlike in most of the world, we publish first and patent later. Besides a virtuous cycle of innovation, there needs to be a virtuous cycle of financing. While much of the academia depends upon public funding, the sector should be also be supported by angel investors with risk capital. But investors and capital markets are risk averse. There is a poor investment climate especially for long-term gestation.”  
- Kiran Mazumdar-Shaw, CMD, Biocon ([The Hindu](#))
- “India has to strengthen the area of vaccine production immensely as the country has only six vaccines which are available in almost all the countries. There are about 30 vaccines available in the world for curing various diseases. More innovations are required for inventing vaccines and new drugs for curing diseases like those which have no cure at all. The manufacturing companies which are investing more on R&D for new molecules can create waves in the world.”  
- Dr. V K Subburaju, Secretary, Department of Pharmaceuticals ([Pharmabiz](#))